Strategic Partnerships Jaguar Gene Therapy has established a notable partnership with Andelyn Biosciences for late-stage manufacturing of the investigational gene therapy JAG201, highlighting collaboration opportunities with CDMOs and contract manufacturing services in the gene therapy space.

Pipeline Expansion The company's focus on developing therapies for severe genetic diseases such as Type 1 galactosemia, autism spectrum disorder, Phelan-McDermid syndrome, and Type 1 diabetes presents avenues for supply chain and manufacturing partners looking to support expanding clinical programs.

Facility Investment The planned $125 million investment in a 174,000-square-foot manufacturing facility in North Carolina signals a significant capacity increase, offering opportunities for vendors involved in large-scale biomanufacturing equipment, facility services, and logistics support.

Funding & Innovation Aligned with investors like Samsung Ventures and JDRF T1D Fund, Jaguar Gene Therapy is positioned for growth, creating opportunities for innovative technology providers focused on gene therapy delivery systems, regulatory compliance, and research collaborations.

Growth Potential With a revenue range of $10M to $25M and a small but growing team, Jaguar Gene Therapy is open to partnerships for expanding clinical development, regulatory expertise, and commercialization strategies in the competitive gene therapy industry.